J&J COVID-19 shot gets better boost from Moderna or Pfizer in NIH study

imageStock Markets5 minutes ago (Oct 13, 2021 06:16PM ET)

(C) Reuters. FILE PHOTO: Vials of coronavirus disease (COVID-19) vaccines of Pfizer-BioNTech and Moderna are seen in the town of Ricany near Prague, Czech Republic, February 25, 2021. REUTERS/David W Cerny/File Photo/File Photo/File Photo

By Carl O’Donnell

(Reuters) – People who got Johnson & Johnson (NYSE:JNJ) Inc’s COVID-19 vaccine as a first shot had a stronger immune response when boosted with vaccines from Pfizer (NYSE:PFE) Inc/BioNTech SE or Moderna (NASDAQ:MRNA) Inc, a study run by the National Institutes of Health showed on Wednesday.

The study, which is preliminary and hasn’t been peer reviewed, is the latest challenge to J&J’s efforts to use its COVID-19 vaccine as a booster in the United States.

The study, which included more than 450 adults who received initial shots from Pfizer, Moderna, or Johnson & Johnson, showed that “mixing and matching” booster shots of different types is safe in adults. Moderna’s and Pfizer’s vaccines are based on messenger RNA while J&J’s uses viral vector technology.

It comes as an advisory group to the U.S. Food and Drug Administration is preparing to meet later this week to discuss the merits of a booster shot for Moderna and J&J vaccines.

FDA officials on Wednesday said J&J’s regulatory submission for its planned booster raised red flags including small sample sizes and data based on tests that had not been validated.

U.S. health officials have been under pressure to offer advice on booster doses of the J&J and Moderna COVID-19 vaccines after the White House announced in August it planned to roll out boosters beginning last month for most adults.

The NIH study contrasted the safety and immune response of volunteers who were boosted with the same type of shot they had been given for their initial vaccination with those who received a different type of shot as a booster.

Mixing and matching doses for a booster produced similar side effects to those seen in primary inoculations and raised no significant safety concerns, the study said.

The study of the three COVID-19 vaccines currently authorized in the United States showed that using different types of shots as boosters generally appeared to produce a comparable or higher antibody response than using the same type.

The trial took place in 10 U.S. cities and used a total of nine combinations of initial shots and boosters.

Mixing booster doses “may offer immunological advantages to optimize the breadth and longevity of protection achieved with currently available vaccines,” researchers wrote in the study.

J&J COVID-19 shot gets better boost from Moderna or Pfizer in NIH study

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.